Efficacy and safety of medical treatment of chronic anxiety disorders in diabetic patients

Aim. To study efficiency and safety of hydroxizine (H) and tofisopam (T) therapy in DM patients with generalized organic anxiety disorders and subsyndromicanxiety the overall prevalence of which among diabetic patients amounts to 45-50%. Materials and methods. This open prospective randomized comp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Elena Georgievna Starostina, Elena Nikolaevna Moshnyaga, Aleksey Evgen'evich Bobrov
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2010
Materias:	diabetes mellitus anxiety disorders therapy hydroxizine tofisopam Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/515615d0a534444691ee6ae05f6cc5de
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:515615d0a534444691ee6ae05f6cc5de
record_format	dspace
spelling	oai:doaj.org-article:515615d0a534444691ee6ae05f6cc5de2021-11-14T09:00:15ZEfficacy and safety of medical treatment of chronic anxiety disorders in diabetic patients2072-03512072-037810.14341/2072-0351-5488https://doaj.org/article/515615d0a534444691ee6ae05f6cc5de2010-09-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5488https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim. To study efficiency and safety of hydroxizine (H) and tofisopam (T) therapy in DM patients with generalized organic anxiety disorders and subsyndromicanxiety the overall prevalence of which among diabetic patients amounts to 45-50%. Materials and methods. This open prospective randomized comparative study included 60 DM patients with anxiety disorders (AD) of whom 95%presented with arterial hypertension. The medicines were prescribed at mean therapeutic doses for 3 months followed by 1 month withdrawal period.The efficiency of anxiolytics was estimated from dynamic patterns of reactive anxiety (RA), personal anxiety (PA, Spielberger scale), somatic anxietysymptoms (Giessen questionnaire), HbA1c level, systolic and diastolic AP (SAP, DAP), heart rate. Results. Therapy with anxiolytics for 3 months resulted in the decrease of the HbA1c level from 7.9?1.4 to 7.4?1.4%, total somatic anxiety scorefrom 38.0?13.2 to 31.5?12.2, PA from 52.5?9.7 to 47.1?8.8, RA from 32.3?9.0 to 25.5?9.3, SAP from 141.4?12.4 to 129.8?13.5 mmHg,DAP from 82.3?7.4 to 77.8?8.6 mm Hg, HR from 76.3?9.5 to 72.7-5.6 (in all cases pElena Georgievna StarostinaElena Nikolaevna MoshnyagaAleksey Evgen'evich BobrovEndocrinology Research Centrearticlediabetes mellitusanxiety disorderstherapyhydroxizinetofisopamNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 3, Pp 52-55 (2010)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus anxiety disorders therapy hydroxizine tofisopam Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus anxiety disorders therapy hydroxizine tofisopam Nutritional diseases. Deficiency diseases RC620-627 Elena Georgievna Starostina Elena Nikolaevna Moshnyaga Aleksey Evgen'evich Bobrov Efficacy and safety of medical treatment of chronic anxiety disorders in diabetic patients
description	Aim. To study efficiency and safety of hydroxizine (H) and tofisopam (T) therapy in DM patients with generalized organic anxiety disorders and subsyndromicanxiety the overall prevalence of which among diabetic patients amounts to 45-50%. Materials and methods. This open prospective randomized comparative study included 60 DM patients with anxiety disorders (AD) of whom 95%presented with arterial hypertension. The medicines were prescribed at mean therapeutic doses for 3 months followed by 1 month withdrawal period.The efficiency of anxiolytics was estimated from dynamic patterns of reactive anxiety (RA), personal anxiety (PA, Spielberger scale), somatic anxietysymptoms (Giessen questionnaire), HbA1c level, systolic and diastolic AP (SAP, DAP), heart rate. Results. Therapy with anxiolytics for 3 months resulted in the decrease of the HbA1c level from 7.9?1.4 to 7.4?1.4%, total somatic anxiety scorefrom 38.0?13.2 to 31.5?12.2, PA from 52.5?9.7 to 47.1?8.8, RA from 32.3?9.0 to 25.5?9.3, SAP from 141.4?12.4 to 129.8?13.5 mmHg,DAP from 82.3?7.4 to 77.8?8.6 mm Hg, HR from 76.3?9.5 to 72.7-5.6 (in all cases p
format	article
author	Elena Georgievna Starostina Elena Nikolaevna Moshnyaga Aleksey Evgen'evich Bobrov
author_facet	Elena Georgievna Starostina Elena Nikolaevna Moshnyaga Aleksey Evgen'evich Bobrov
author_sort	Elena Georgievna Starostina
title	Efficacy and safety of medical treatment of chronic anxiety disorders in diabetic patients
title_short	Efficacy and safety of medical treatment of chronic anxiety disorders in diabetic patients
title_full	Efficacy and safety of medical treatment of chronic anxiety disorders in diabetic patients
title_fullStr	Efficacy and safety of medical treatment of chronic anxiety disorders in diabetic patients
title_full_unstemmed	Efficacy and safety of medical treatment of chronic anxiety disorders in diabetic patients
title_sort	efficacy and safety of medical treatment of chronic anxiety disorders in diabetic patients
publisher	Endocrinology Research Centre
publishDate	2010
url	https://doaj.org/article/515615d0a534444691ee6ae05f6cc5de
work_keys_str_mv	AT elenageorgievnastarostina efficacyandsafetyofmedicaltreatmentofchronicanxietydisordersindiabeticpatients AT elenanikolaevnamoshnyaga efficacyandsafetyofmedicaltreatmentofchronicanxietydisordersindiabeticpatients AT alekseyevgenevichbobrov efficacyandsafetyofmedicaltreatmentofchronicanxietydisordersindiabeticpatients
_version_	1718429647672180736

Efficacy and safety of medical treatment of chronic anxiety disorders in diabetic patients

Ejemplares similares